Assessment of treatment efficacy in acute myeloid leukemia (AML) is highly relevant for further treatment stratification. In clinical trials, measurable residual disease (MRD) assessment has improved prognostic precision, providing a strong rationale for it’s use to guide treatment, and compare therapy efficacy. MRD can be evaluated using an array of multiparameter flow cytometry and molecular approaches. However, these methods have not been standardized, making their utilization in clinical practice challenging.
In today’s podcast, Marion Subklewe, MD, of Ludwig Maximilian University Hospital Munich, Munich, Germany, chairs an insightful discussion with Sylvie Freeman, MBChB, MRCP, DPhil, FRCPath, of University of Birmingham, Birmingham, UK, and Jorge Sierra, MD, PhD, of Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, on utilizing MRD for AML in the clinical setting.